Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EnzySurge, a provider of innovative solutions for chronic wound management, has secured $2 million in private investment and expects to raise it further to $3 million.
Subscribe to our email newsletter
With this capital, the company intends to accelerate the FDA approval process and expand its marketing efforts, in order to launch its first product during the H2 of 2008. EnzySurge’s DermaStream product line is based on its patented Continuous Streaming Therapy (CST) technology, a new comprehensive modality for chronic wound management.
Amir Shiner, CEO of EnzySurge, said: “In light of encouraging clinical results, a positive regulatory environment and anticipated fast-track FDA approval, we expect to be able to increase our recent investment round from $2 million to $3 million.”